Trials / Unknown
UnknownNCT04348643
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chongqing Precision Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.
Detailed description
CEA is a classic tumor marker, especially in more than 80% of colorectal cancer patients. In normal tissue cells, only a small amount of CEA is expressed in the cell membrane of the digestive tract cells, and the CEA is expressed toward the cell cavity under physiological conditions to avoid recognition by CAR-T cells targeting CEA. This is a study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy,and obtain the recommended dose and infusion plan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CEA CAR-T cells | CEA-CAR-T cells will be administered intravenously. |
Timeline
- Start date
- 2020-02-20
- Primary completion
- 2023-12-31
- Completion
- 2024-04-30
- First posted
- 2020-04-16
- Last updated
- 2023-04-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04348643. Inclusion in this directory is not an endorsement.